A second peptide, VDAC1-derived N-terminal peptide, was also developed and found to induce cancer cell death [29] and potentially serve as a new therapeutic strategy for amyotrophic lateral sclerosis (ALS) [29]. The gene discussed is VDAC1; the disease is amyotrophic lateral sclerosis.